PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Julia:ReplicateBE – release 0.2.0

Опубликовано 26 октября, 201926 октября, 2019 frozencat

doiGitHub

Вот и подоспел релиз 0.2.0 для оценки параметров смешанной модели репликативного дизайна биоэквивалентности по методу С (EMA) – FDA model.

 

Рубрики: IT, Julia, Mixed Model, Биоэквивалентность

Навигация по записям

Предыдущая запись: ClinicalTrialUtilities: обзор
Следующая запись: Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170805-WA0001
20170802 185217
20170729 215051
20170730 142936
20180814 182629
20170803 001141
  • Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Human medicines European public assessment report (EPAR): Bortezomib Sun, bortezomib, Date of authorisation: 22/07/2016, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • FDA approves new treatment for acromegaly, a rare endocrine disorder
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-14 By FDA
  • Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Competitive Generic Therapy Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-14 By FDA
  • Human medicines European public assessment report (EPAR): Menveo, meningococcal group A, C, W-135 and Y conjugate vaccine, Date of authorisation: 15/03/2010, Date of refusal: 17/12/2009, Revision: 39, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Human medicines European public assessment report (EPAR): Vaxelis, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed), Date of authorisation: 15/02/2016, Revision: 17, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Date of authorisation: 27/10/2020, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Health and Natural Beauty USA Corp. - 700187 - 07/28/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-14 By FDA
  • Human medicines European public assessment report (EPAR): Okedi, risperidone, Date of authorisation: 14/02/2022, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Allovate Therapeutics, LLC - 708912 - 09/30/2025
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-14 By FDA
  • Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 58, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Human medicines European public assessment report (EPAR): Evusheld, tixagevimab,cilgavimab, Date of authorisation: 25/03/2022, Revision: 10, Status: Withdrawn
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-14
  • List of Drug Master Files (DMFs)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-14 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.